Date: 2017-07-24
Type of information: Clinical research agreement
Compound: SGN-LIV1A and atezolizumab
Company: Seattle Genetics (USA - WA) Genentech, a member of Roche Group (USA - CA - Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: clinical research
Action mechanism:
- antibody drug conjugate/ADC. SGN-LIV1A is an ADC that combines a humanized anti-LIV-1 monoclonal antibody linked to a synthetic cytotoxic cell-disrupting agent, monomethyl auristatin E (MMAE). The ADC is designed to bind to LIV-1 proteins, which are expressed in most subtypes of metastatic breast cancer, and to release the potent cytotoxic agent MMAE into the target cell upon internalization into LIV-1-expressing tumor cells.
- immunotherapy product/monoclonal antibody/immune checkpoint inhibitor. Atezolizumab (MPDL3280A) is a monoclonal antibody designed to make cancer cells more vulnerable to the body’s immune system by interfering with a protein called PD-L1. PD-L1 is found on the surface of cells in tumours and is believed to act as a “stop sign,” preventing the immune system from destroying cancer cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells. MPDL3280A is being studied in clinical trials to understand whether blocking PD-L1 will help the immune system respond to cancer.
Disease: triple-negative breast cancer (TNBC)
Details:
- • On July 24, 2017, Seattle Genetics announced a clinical collaboration agreement with Genentech for the evaluation of its investigational antibody-drug conjugate SGN-LIV1A in combination with atezolizumab (Tecentriq®) in patients with metastatic triple-negative breast cancer.
- SGN-LIV1A administered in combination with atezolizumab will be evaluated in a phase 1b/2 clinical study as second-line therapy in patients with metastatic TNBC who have not been previously treated with immunotherapy. This randomized, controlled study is anticipated to enroll up to 45 patients in the treatment arm.
- Seattle Genetics and Genentech will test the experimental combination in MORPHEUS, Roche's Novel Cancer Immunotherapy Development Platform. MORPHEUS is a phase 1b/2 adaptive platform to develop combinations of cancer immunotherapies rapidly and efficiently.
- Under the terms of the collaboration agreement, Genentech will manage the study operations for the phase 1b/2 trial. Seattle Genetics will retain global development and commercialization rights to SGN-LIV1A.
Financial terms:
Latest news:
Is general: Yes
